Hong Kong's hot stock | Jiufang Pharmaceutical-B (02595.HK) rose more than 6%. GFH375 has the best potential in the same category and is conducting a Phase III registration clinical trial for second-line and above pancreatic cancer.
According to the Securities Times APP, Sino Biopharmaceutical Limited-B (02595.HK) rose by over 6%, as of the time of writing, it rose by 6.13% to 34.98 Hong Kong dollars, with a turnover of 90.0892 million Hong Kong dollars.
Latest
